Mohamed Omar
About Mohamed Omar
Mohamed Omar is the Director of Health Services and Outcomes Research at Bristol-Myers Squibb in the Greater Atlanta Area, with extensive experience in health economics and outcomes research.
Current Role at Bristol-Myers Squibb
Mohamed Omar is currently serving as the Director of Health Services and Outcomes Research at Bristol-Myers Squibb in the Greater Atlanta Area. He has held this position since August 2014. In this role, he leads a team focused on health services and outcomes research, engaging in high-level discussions with key access customers to address issues specific to BMS products. His responsibilities include developing and maintaining sustainable customer relationships and discussing a wide range of scientific, health economic, epidemiology, and quality of life information.
Previous Experience at Novartis
Before joining Bristol-Myers Squibb, Mohamed Omar worked at Novartis in various capacities. From 2008 to 2014, he was the Therapeutic Area Leader for Global Scientific Operations in Global Medical Affairs. He also served as the Therapeutic Area Head for Global Health Economics and Outcomes Research from 2006 to 2007. Earlier in his career, from 2002 to 2006, he held the position of Assistant Director in US Health Economics and Outcomes Research. During his tenure at Novartis, he gained significant experience at both global and US levels, contributing to the development and commercialization of therapies.
Educational Background
Mohamed Omar completed his PhD and RPh in Health Economics and Outcomes Research at The University of Texas at Austin, where he studied from 1996 to 2001. This extensive educational background has provided him with the foundational knowledge and skills necessary for his various roles in the pharmaceutical industry.
Industry Expertise
With 12 years of solid industry experience, Mohamed Omar possesses expertise in leading the development and implementation of robust payer value proposition strategies. His skills also include medical expert engagement to support both the development and commercialization of therapies. His track record spans both global and US levels, making him well-versed in the intricacies of health economics and outcomes research.